NRX Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 14, 2025
NRXP$2.380.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Changes in Stockholders’ Equity (Deficit)
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’** (DEFICIT) EQUITY**
(in thousands, except share data)
| Series A Preferred Stock · Common Stock · Additional Paid-in- · Accumulated · Accumulated Other Comprehensive Income · Total Stockholders’ Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | (Loss) | (Deficit) | |
| Balance - December 31, 2022 | — | $— | 6,644,299 | $7 | $230,399 | $(222,997) | $— | $7,409 |
| Common stock and warrants issued, net of issuance costs $2,519 | — | — | 1,353,667 | 1 | 8,121 | — | — | 8,122 |
| Preferred stock and warrants issued, net of issuance costs $27 | 3,000,000 | 3 | — | — | 1,168 | — | — | 1,171 |
| Change in fair value of convertible note attributed to credit risk | — | — | — | — | — | — | (3) | (3) |
| Shares issued as repayment of principal and interest for convertible note | — | — | 326,423 | — | 982 | — | — | 982 |
| Common stock issued to settle GEM settlement liability | — | — | 67,568 | — | 250 | — | — | 250 |
| Adjustment for deferred offering cost settlement | — | — | — | — | 99 | — | — | 99 |
| Stock-based compensation | — | — | — | — | 387 | — | — | 387 |
| Net loss | — | — | — | — | — | (30,150) | — | (30,150) |
| Balance December 31, 2023 | 3,000,000 | $3 | 8,391,956 | $8 | $241,406 | $(253,147) | $(3) | $(11,733) |
| Conversion of Series A preferred stock into common stock | (3,000,000) | (3) | 300,000 | — | 3 | — | — | — |
| At-the-market “ATM” offering, net of offering costs of $197 | — | — | 385,515 | 1 | 1,626 | — | — | 1,627 |
| Common stock and warrants issued, net of issuance costs $975 | — | — | 1,273,050 | 1 | 3,256 | — | — | 3,257 |
| Common stock and warrants issued in private placement | — | — | 270,000 | 1 | 1,026 | — | — | 1,027 |
| Vesting of restricted stock awards | — | — | 57,500 | — | — | — | — | — |
| Shares issued as repayment of principal and interest for convertible note | — | — | 3,820,444 | 4 | 5,859 | — | — | 5,863 |
| Issuance of shares related to reverse stock split | — | — | 73,040 | — | — | — | — | — |
| Contract cost related to Alvogen termination (see Note 6) | — | — | — | — | 1,336 | — | — | 1,336 |
| Common stock issued in exchange for services | — | — | 20,000 | — | 37 | — | — | 37 |
| Reclassification of AOCI upon settlement of Streeterville Note | — | — | — | — | — | — | 3 | 3 |
| Stock-based compensation | — | — | — | — | 486 | — | — | 486 |
| Net loss | — | — | — | — | — | (25,126) | — | (25,126) |
| Balance - December 31, 2024 | — | $— | 14,591,505 | $15 | $255,035 | $(278,273) | $— | $(23,223) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.